Investors

Corporate Overview

BioSpecifics has developed a first-in-class collagenase-based product collagenase clostridium histolyticum (CCH) marketed in the U.S. as XIAFLEX®. XIAFLEX® is marketed in the US by our partner Endo Pharmaceuticals for the treatment of Dupuytren's contracture and Peyronie's disease. In addition to investing in the development of several potential new indications for its collagenase-based technology, BioSpecifics is seeking to partner with companies that possess interesting new technologies and products in specialty markets.

Latest News